Isobolographic characterization of the anticonvulsant interaction profiles of levetiracetam in combination with clonazepam, ethosuximide, phenobarbital and valproate in the mouse pentylenetetrazole-induced seizure model

Seizure

Volumn 18, Issue 9, 2009, Pages 607-614

  Dudra Jastrzebska, Monika ^a,b   Andres Mach, Marta M ^b   Ratnaraj, Neville ^c   Patsalos, Philip N ^c   Czuczwar, Stanislaw J ^a,b   Luszczki, Jarogniew J ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antiepileptic drugs; Isobolographic analysis; Levetiracetam; Pharmacodynamic interactions; Pharmacokinetic interactions

Indexed keywords

CLONAZEPAM; ETHOSUXIMIDE; ETIRACETAM; PENTETRAZOLE; PHENOBARBITAL; VALPROIC ACID; ANTICONVULSIVE AGENT; CONVULSANT AGENT; DRUG DERIVATIVE; PIRACETAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; AVOIDANCE BEHAVIOR; CLONIC SEIZURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BRAIN LEVEL; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG INTERACTION; DRUG MIXTURE; DRUG POTENTIATION; DRUG SAFETY; GRIP STRENGTH; LONG TERM MEMORY; MALE; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG COMBINATION; SEIZURE;

ANIMALS; ANTICONVULSANTS; CLONAZEPAM; CONVULSANTS; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ETHOSUXIMIDE; MALE; MICE; PENTYLENETETRAZOLE; PHENOBARBITAL; PIRACETAM; SEIZURES; VALPROIC ACID;

EID: 73349086269     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seizure.2009.06.009     Document Type: Article

References (62)

1. Kwan P., and Brodie M.J. Early identification of refractory epilepsy. New England Journal of Medicine 342 (2000) 314-319
2. Kwan P., and Brodie M.J. Epilepsy after the first drug fails: substitution or add-on?. Seizure 9 (2000) 464-468
3. Reynolds E.H., and Shorvon S.D. Single drug or combination therapy for epilepsy?. Drugs 21 (1981) 374-382
4. Deckers C.L., Czuczwar S.J., Hekster Y.A., Keyser A., Kubova H., Meinardi H., et al. Selection of antiepileptic drug polytherapy based on mechanism of action: the evidence reviewed. Epilepsia 41 (2000) 1364-1374
5. Perucca E. Pharmacological principles as a basis for polytherapy. Acta Neurologica Scandinavica Suppl. 162 (1995) 31-34
6. Patsalos P.N., Fröscher W., Pisani F., and van Rijn C.M. The importance of drug interactions in epilepsy therapy. Epilepsia 43 (2002) 365-385
7. Patsalos P.N., and Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurology 2 (2003) 347-356
8. Patsalos P.N., and Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurology 2 (2003) 473-481
9. Stephen L.J., and Brodie M.J. Seizure freedom with more than one antiepileptic drug. Seizure 11 (2002) 349-351
10. Luszczki J.J., Andres M.M., Czuczwar P., Cioczek-Czuczwar A., Ratnaraj N., Patsalos P.N., et al. Pharmacodynamic and pharmacokinetic characterization of interactions between levetiracetam and numerous antiepileptic drugs in the mouse maximal electroshock seizure model: an isobolographic analysis. Epilepsia 47 (2006) 10-20
11. Luszczki J.J., Andres M.M., Czuczwar P., Cioczek-Czuczwar A., Wojcik-Cwikla J., Ratnaraj N., et al. Levetiracetam selectively potentiates the acute neurotoxic effects of topiramate and carbamazepine in the rotarod test in mice. European Neuropsychopharmacology 15 (2005) 609-616
12. Luszczki J.J., Andres-Mach M.M., Ratnaraj N., Patsalos P.N., and Czuczwar S.J. Levetiracetam and felbamate interact both pharmacodynamically and pharmacokinetically: an isobolographic analysis in the mouse maximal electroshock model. Epilepsia 48 (2007) 806-815
13. Berkovic S.F., Knowlton R.C., Leroy R.F., Schiemann J., and Falter U. Levetiracetam N01057 Study Group. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 69 (2007) 1751-1760
14. Alsaadi T.M., Shatzel A., Marquez A.V., Jorgensen J., and Farias S. Clinical experience of levetiracetam monotherapy for adults with epilepsy: 1-year follow-up study. Seizure 14 (2005) 139-142
15. Ben-Menachem E., and Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 41 (2000) 1276-1283
16. Cereghino J.J., Biton V., Abou-Khalil B., Dreifuss F., Gauer L.J., and Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 55 (2000) 236-242
17. Grant R., and Shorvon S.D. Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy. Epilepsy Research 42 (2000) 89-95
18. Khurana D.S., Kothare S.V., Valencia I., Melvin J.J., and Legido A. Levetiracetam monotherapy in children with epilepsy. Pediatric Neurology 36 (2007) 227-230
19. Sharief M.K., Singh P., Sander J.W.A.S., Patsalos P.N., and Shorvon S.D. Efficacy and tolerability study of ucb L059 in patients with refractory epilepsy. Journal of Epilepsy 9 (1996) 106-112
20. Greenhill L., Betts T., and Smith K. Effect of levetiracetam on resistant juvenile myoclonic epilepsy. Epilepsia 42 Suppl. 7 (2001) 179 [abstract]
21. Kumar S.P., and Smith P.E. Levetiracetam as add-on therapy in generalised epilepsies. Seizure 13 (2004) 475-477
22. Specchio L.M., Gambardella A., Giallonardo A.T., Michelucci R., Specchio N., Boero G., et al. Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy. Epilepsy Research 71 (2006) 32-39
23. Genton P., and Gelisse P. Antimyoclonic effect of levetiracetam. Epileptic Disorders 2 (2000) 112-209
24. Kasteleijn-Nolst Trenite D.G., Marescaux C., Stodieck S., Edelbroek P.M., and Oosting J. Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam. Epilepsy Research 25 (1996) 225-230
25. Glauser T.A., Ayala R., Elterman R.D., Mitchell W.G., Van Orman C.B., Gauer L.J., et al. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 66 (2006) 1654-1660
26. Tan M.J., and Appleton R.E. Efficacy and tolerability of levetiracetam in children aged 10 years and younger: a clinical experience. Seizure 13 (2004) 142-145
27. Löscher W., and Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Research 2 (1988) 145-181
28. Gower A.J., Hirsch E., Boehrer A., Noyer M., and Marescaux C. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Research 22 (1995) 207-213
29. Gower A.J., Noyer M., Verloes R., Gobert J., and Wulfert E. Ucb L059 a novel anti-convulsant drug: pharmacological profile in animals. European Journal of Pharmacology 222 (1992) 193-203 [erratum published in: European Journal of Pharmacology 1993;230:389]
30. Klitgaard H., Matagne A., Gobert J., and Wulfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. European Journal of Pharmacology 353 (1998) 191-206
31. Löscher W., Hönack D., and Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. Journal of Pharmacology and Experimental Therapeutics 284 (1998) 474-479
32. Löscher W., and Hönack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. European Journal of Pharmacology 232 (1993) 147-158
33. Marrosu F., Bortolato M., Frau R., Orru M., Puligheddu M., Fa M., et al. Levetiracetam attenuates spontaneous spike-and-wave discharges in DBA/2J mice. Epilepsy Research 75 (2007) 224-227
34. Barton M.E., Klein B.D., Wolf H.H., and White H.S. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Research 47 (2001) 217-227
35. Vinogradova L.V., and van Rijn C.M. Anticonvulsive and antiepileptogenic effects of levetiracetam in the audiogenic kindling model. Epilepsia 49 (2008) 1160-1168
36. Margineanu D.G., Matagne A., Kaminski R.M., and Klitgaard H. Effects of chronic treatment with levetiracetam on hippocampal field responses after pilocarpine-induced status epilepticus in rats. Brain Research Bulletin 77 (2008) 282-285
37. Madeja M., Margineanu D.G., Gorji A., Siep E., Boerrigter P., Klitgaard H., et al. Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action?. Neuropharmacology 45 (2003) 661-671
38. Lukyanetz E.A., Shkryl V.M., and Kostyuk P.G. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 43 (2002) 9-18
39. 2+) current in pyramidal neurones of rat hippocampal slices. Neuroscience Letters 306 (2001) 5-8
40. 2+ currents. Seizure 10 (2001) 279-286
41. Rigo J.M., Hans G., Nguyen L., Rocher V., Belachew S., Malgrange B., et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. British Journal of Pharmacology 136 (2002) 659-672
42. Palma E., Roseti C., Maiolino F., Fucile S., Martinello K., Mazzuferi M., et al. GABA(A)-current rundown of temporal lobe epilepsy is associated with repetitive activation of GABA(A) "phasic" receptors. Proceedings of the National Academy of Sciences of the United States of America 104 (2007) 20944-20948
43. Nagarkatti N., Deshpande L.S., and DeLorenzo R.J. Levetiracetam inhibits both ryanodine and IP3 receptor activated calcium induced calcium release in hippocampal neurons in culture. Neuroscience Letters 436 (2008) 289-293
44. Lee C.H., Lee C.Y., Tsai T.S., and Liou H.H. PKA-mediated phosphorylation is a novel mechanism for levetiracetam, an antiepileptic drug, activating ROMK1 channels. Biochemical Pharmacology 76 (2008) 225-235
45. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proceedings of the National Academy of Sciences of the United States of America 101 (2004) 9861-9866
46. Sills G.J., Butler E., Thompson G.G., and Brodie M.J. Pharmacodynamic interaction studies with topiramate in the pentylenetetrazol and maximal electroshock seizure models. Seizure 13 (2004) 287-295
47. Mazarati A.M., Baldwin R., Klitgaard H., Matagne A., and Wasterlain C.G. Anticonvulsant effects of levetiracetam and levetiracetam-diazepam combinations in experimental status epilepticus. Epilepsy Research 58 (2004) 167-174
48. Dudra-Jastrzebska M., Andres-Mach M.M., Sielski M., Ratnaraj N., Patsalos P.N., Czuczwar S.J., et al. Pharmacodynamic and pharmacokinetic interaction profiles of levetiracetam in combination with gabapentin, tiagabine and vigabatrin in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis. European Journal of Pharmacology 605 (2009) 87-94
49. Kaminski R.M., Matagne A., Patsalos P.N., and Klitgaard H. Benefits of combination therapy in epilepsy: a review of preclinical evidence with levetiracetam. Epilepsia 50 (2009) 387-397
50. Donato Di Paola E., Gareri P., Davoli A., Gratteri S., Scicchitano F., Naccari C., et al. Influence of levetiracetam on the anticonvulsant efficacy of conventional antiepileptic drugs against audiogenic seizures in DBA/2 mice. Epilepsy Research 75 (2007) 112-121
51. Sisodiya S.M., Sander J.W., and Patsalos P.N. Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction. Epilepsy Research 48 (2002) 217-219
52. Glauser T.A., Pellock J.M., Bebin E.M., Fountain N.B., Ritter F.J., Jensen C.M., et al. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia 43 (2002) 518-524
53. Löscher W., Hönack D., Fassbender C.P., and Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Research 8 (1991) 171-189
54. Lapin I.P. Only controls: effect of handling, sham injection, and intraperitoneal injection of saline on behavior of mice in an elevated plus-maze. Journal of Pharmacological and Toxicological Methods 34 (1995) 73-77
55. Litchfield J.T., and Wilcoxon F. A simplified method of evaluating dose-effect experiments. Journal of Pharmacology and Experimental Therapeutics 96 (1949) 99-113
56. Porreca F., Jiang Q., and Tallarida R.J. Modulation of morphine antinociception by peripheral [Leu5]enkephalin: a synergistic interaction. European Journal of Pharmacology 179 (1990) 463-468
57. Tallarida R.J. Drug synergism and dose-effect data analysis (2000), Chapman & Hall/CRC, Boca Raton, FL
58. Ratnaraj N., Doheny H.C., and Patsalos P.N. A micromethod for the determination of the new antiepileptic drug levetiracetam (ucb LO59) in serum or plasma by high performance liquid chromatography. Therapeutic Drug Monitoring 18 (1996) 154-157
59. Boissier J.R., Tardy J., and Diverres J.C. Une nouvelle méthode simple pour explorer l'action tranquilisante: le test de la cheminée. Medicina Experimentalis (Basel) 3 (1960) 81-84
60. Venault P., Chapouthier G., de Carvalho L.P., Simiand J., Morre M., Dodd R.H., et al. Benzodiazepines impair and beta-carbolines enhance performance in learning and memory tasks. Nature 321 (1986) 864-866
61. Meyer O.A., Tilson H.A., Byrd W.C., and Riley M.T. A method for the routine assessment of fore- and hindlimb grip strength of rats and mice. Neurobehavioral Toxicology 1 (1979) 233-236
62. Patsalos P.N. Levetiracetam: pharmacology and therapeutics in the treatment of epilepsy and other neurological conditions. Reviews in Contemporary Pharmacotherapy 13 (2004) 1-168